Dainippon Pharmaceutical , Meiji Seika Kaisha, Ltd. Jointly Market New Formulations For Ebastel Antiallergic Agent
10/19/2005 5:09:29 PM
Tokyo (JCNN) - On July 11, Dainippon Pharmaceutical (TSE: 4506) and Meiji Seika Kaisha (TSE: 2202) jointly launched Ebastel OD Tablet 5mg and Ebastel OD Tablet 10mg, new formulations for the antiallergic agent Ebastel.
Based on Dainippon Pharmaceutical's proprietary drug formulation technology, the new products are easily disintegrated in the mouth without water.
comments powered by